Date: 2015-10-28
Type of information: Development agreement
Compound: trastuzumab (biosimilar product)
Company: ProBioGen (Germany) Bio Farma Indonesia (Indonesia)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism: biosimilar/monoclonal antibody. Trastuzumab is a recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2.
Disease:
Details: * On October 28, 2015, ProBioGen and Bio Farma signed an agreement for the development of a biosimilar trastuzumab for cancer treatment. The goal of the co-operation is the supply of the Indonesian patients with cost-effective high quality biopharmaceuticals. Under the terms of the agreement ProBioGen will develop a highly efficient manufacturing process based on a specifically designed recombinant CHO-cell line, conduct engineering runs and the industrial scale-up. The turn-key process, including state-of-the-art analytics, will then be transferred to Indonesia to enable local market production. The agreement is fee-for-service based, license and royalty-free.
Financial terms:
Latest news:
